CN101438148B - 利用质谱判别异构体的方法 - Google Patents

利用质谱判别异构体的方法 Download PDF

Info

Publication number
CN101438148B
CN101438148B CN200780016028.2A CN200780016028A CN101438148B CN 101438148 B CN101438148 B CN 101438148B CN 200780016028 A CN200780016028 A CN 200780016028A CN 101438148 B CN101438148 B CN 101438148B
Authority
CN
China
Prior art keywords
adma
mass
sdma
sample
charge ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780016028.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN101438148A (zh
Inventor
布拉斯·瑟达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruifudi Health Science Co
Original Assignee
PerkinElmer LAS Inc
PerkinElmer Health Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PerkinElmer LAS Inc, PerkinElmer Health Sciences Inc filed Critical PerkinElmer LAS Inc
Publication of CN101438148A publication Critical patent/CN101438148A/zh
Application granted granted Critical
Publication of CN101438148B publication Critical patent/CN101438148B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN200780016028.2A 2006-03-02 2007-03-02 利用质谱判别异构体的方法 Active CN101438148B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77848306P 2006-03-02 2006-03-02
US60/778,483 2006-03-02
PCT/US2007/005279 WO2007103124A2 (en) 2006-03-02 2007-03-02 Methods for distinguishing isomers using mass spectrometry

Publications (2)

Publication Number Publication Date
CN101438148A CN101438148A (zh) 2009-05-20
CN101438148B true CN101438148B (zh) 2014-01-22

Family

ID=38475391

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780016028.2A Active CN101438148B (zh) 2006-03-02 2007-03-02 利用质谱判别异构体的方法

Country Status (10)

Country Link
US (1) US20080073500A1 (https=)
EP (1) EP1996923B1 (https=)
JP (1) JP2009528544A (https=)
CN (1) CN101438148B (https=)
AU (1) AU2007224240B2 (https=)
BR (1) BRPI0708485A2 (https=)
CA (1) CA2644499A1 (https=)
DK (1) DK1996923T3 (https=)
ES (1) ES2392629T3 (https=)
WO (1) WO2007103124A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005056408B4 (de) * 2005-05-28 2007-05-31 Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh Verfahren zur Bestimmung der Konzentration von asymmetrischem Dimethylarginin (ADMA)
JP2010540911A (ja) * 2007-10-01 2010-12-24 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド アルコール消費の複合化した代謝産物の分析
CN102421358A (zh) 2009-03-10 2012-04-18 杜克大学 对冠心病和心血管事件风险的预测
AU2015258285B2 (en) * 2009-03-10 2017-09-07 Duke University Predicting coronary artery disease and risk of cardiovascular events
WO2010108180A2 (en) * 2009-03-20 2010-09-23 The Cleveland Clinic Foundation Citrulline, a risk indicator for cardiovascular disease
EP2436025A1 (en) * 2009-05-27 2012-04-04 DH Technologies Development Pte. Ltd. Linear ion trap for msms
JP5746154B2 (ja) * 2009-05-28 2015-07-08 ザ クリーブランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ ＣｌｉｎｉｃＦｏｕｎｄａｔｉｏｎ 疾患の診断および予測のためのトリメチルアミン含有化合物
EP2438441B1 (en) * 2009-06-02 2014-05-21 BIOCRATES Life Sciences AG New biomarkers for assessing kidney diseases
EP2443456A4 (en) * 2009-06-15 2013-02-20 Cleveland Clinic Foundation METABOLITES OF ARGININE METHYLATES AS PREDICTORS OF CARDIOVASCULAR DISEASE RISK
CN102893156A (zh) * 2009-12-21 2013-01-23 爱尔兰国立科克大学 子痫前期风险的检测
US8703424B2 (en) * 2010-03-22 2014-04-22 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
CN107064330B (zh) * 2010-12-28 2022-02-25 探索诊断投资公司 通过质谱法定量胰岛素
CN102154444B (zh) * 2010-12-30 2013-09-25 北京九强生物技术股份有限公司 测定不对称二甲基精氨酸浓度的方法及诊断试剂盒
AU2012271718A1 (en) * 2011-06-16 2014-01-09 Baylor Research Institute Analysis of total homocysteine and methylmalonic acid in plasma by LC-MS/MS from a plasma separator device (PSD)
WO2013140785A1 (ja) * 2012-03-18 2013-09-26 国立大学法人九州大学 疾患サンプル分析装置、分析システム及び分析方法
CN103207173B (zh) * 2013-03-13 2015-06-17 北大工学院绍兴技术研究院 一种酶学检测方法
WO2015044958A1 (en) 2013-09-25 2015-04-02 Council Of Scientific & Industrial Research Quantitation of structural isomers using maldi ms/ms
JP6647224B2 (ja) 2014-06-13 2020-02-14 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド 質量分析を用いる脂質の分析のための方法
EP3259593B1 (en) * 2015-02-20 2022-10-05 IDEXX Laboratories, Inc. Homogenous immunoassay with compensation for background signal
WO2016149220A1 (en) 2015-03-13 2016-09-22 Duke University Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction
CN104849298B (zh) * 2015-05-26 2017-10-31 衢州普林千叶电子科技有限公司 一种用于核磁分析的样品检测分析仪和方法
CN105628623B (zh) * 2015-12-25 2018-08-24 北京市农林科学院 一种鉴别光学异构化合物旋光性的方法
CN107764891B (zh) * 2017-10-16 2020-03-13 杭州先导医药科技有限责任公司 一种恩替卡韦手性异构体的区分测定方法
US10854438B2 (en) * 2018-03-19 2020-12-01 Agilent Technologies, Inc. Inductively coupled plasma mass spectrometry (ICP-MS) with improved signal-to-noise and signal-to-background ratios
US11694886B2 (en) * 2018-11-02 2023-07-04 National University Corporation Kobe University Analysis method, adsorption prevention agent, and analysis kit
US20220276263A1 (en) * 2021-02-19 2022-09-01 Idexx Laboratories, Inc. Mass spectrometric analysis of biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3055142B2 (ja) * 1989-11-24 2000-06-26 株式会社島津製作所 質量分析方法
JP2000111526A (ja) * 1998-09-30 2000-04-21 Hitachi Ltd 質量分析計
US20040191819A1 (en) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use
GB0308967D0 (en) * 2003-04-17 2003-05-28 Univ London Screen for pre-eclampsia
DE102005056408B4 (de) * 2005-05-28 2007-05-31 Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh Verfahren zur Bestimmung der Konzentration von asymmetrischem Dimethylarginin (ADMA)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Edzard Schwedhelm.Quantification of ADMA: analytical approaches.《Vascular Medicine》.2005,第10卷89-95. *
Jens Martens-Lobenhoffer et.Fast and Efficient Determination of Arginine,Symmetric Dimethylarginine,and Asymmetric Dimethylaginine in Biological Fluids by Hydrophilic-Interaction Liquid Chromatography-Electrospray Tandem Mass Spectrometry.《Clinical Chemistry》.2005,第52卷(第3期),488-493. *

Also Published As

Publication number Publication date
CA2644499A1 (en) 2007-09-13
WO2007103124A3 (en) 2008-10-09
AU2007224240B2 (en) 2013-07-25
ES2392629T3 (es) 2012-12-12
AU2007224240A1 (en) 2007-09-13
WO2007103124A2 (en) 2007-09-13
CN101438148A (zh) 2009-05-20
EP1996923A2 (en) 2008-12-03
US20080073500A1 (en) 2008-03-27
JP2009528544A (ja) 2009-08-06
EP1996923A4 (en) 2010-04-07
DK1996923T3 (da) 2012-10-01
BRPI0708485A2 (pt) 2011-05-31
EP1996923B1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
CN101438148B (zh) 利用质谱判别异构体的方法
AU2008247428C1 (en) Detecting succinylacetone
Ng et al. Advances in MALDI mass spectrometry in clinical diagnostic applications
EP2152418B1 (en) Detecting isomers using differential derivatization mass spectrometry
CN115876990A (zh) 鉴别诊断慢性血栓栓塞性肺动脉高压和肺栓塞的标志物及其应用
Matern et al. Mass spectrometry methods for metabolic and health assessment
CN118090930A (zh) 基于血液代谢物的阿尔茨海默症标志物及其应用
AU2014240270B2 (en) Detecting succinylacetone
CN118671212A (zh) 一组用于预测新型冠状病毒感染危重症患者的生物标志物
CN118091146A (zh) 基于血液代谢物的神经退行性疾病标志物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: PerkinElmer Health Sciences, Inc.

Address before: Massachusetts, USA

Applicant before: PerkinElmer LAS, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: PERKINELMER LAS INC. TO: PERKINELMER HEALTH SCIENCES INC.

C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address

Address after: Massachusetts, USA

Patentee after: Ruifudi Health Science Co.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: PerkinElmer Health Sciences, Inc.

Country or region before: U.S.A.

CP03 Change of name, title or address